Gastric Cancer: Genome Damaged by Bugs

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2020 Mar 4

PMID 32123313

Citations 21

Authors

Yanan Zhao

Jinglin Zhang

Alfred S L Cheng

Jun Yu

Ka Fai To

Wei Kang

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The role of the microorganisms in gastric tumorigenesis attracts much attention in recent years. These microorganisms include bacteria, virus, and fungi. Among them, Helicobacter pylori (H. pylori) infection is by far the most important risk factor for GC development, with special reference to the early-onset cases. H. pylori targets multiple cellular components by utilizing various virulence factors to modulate the host proliferation, apoptosis, migration, and inflammatory response. Epstein-Barr virus (EBV) serves as another major risk factor in gastric carcinogenesis. The virus protein, EBER noncoding RNA, and EBV miRNAs contribute to the tumorigenesis by modulating host genome methylation and gene expression. In this review, we summarized the related reports about the colonized microorganism in the stomach and discussed their specific roles in gastric tumorigenesis. Meanwhile, we highlighted the therapeutic significance of eradicating the microorganisms in GC treatment.

Citing Articles

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer.

Zhou Y, Luo Z, Guo J, Wu L, Zhou X, Huang J Cancer Cell Int. 2024; 24(1):338.

PMID: 39402565 PMC: 11476248. DOI: 10.1186/s12935-024-03521-z.

Adipocytes impact on gastric cancer progression: Prognostic insights and molecular features.

Shang J, Zhu J, Bai L, Kulabiek D, Zhai X, Zheng X World J Gastrointest Oncol. 2024; 16(7):3011-3031.

PMID: 39072151 PMC: 11271780. DOI: 10.4251/wjgo.v16.i7.3011.

A prominent role of LncRNA H19 in H. pylori CagA induced DNA damage response and cell malignancy.

He X, Huang T, Wang Q, Bao L, Wang Z, Song H Sci Rep. 2024; 14(1):14185.

PMID: 38902391 PMC: 11190245. DOI: 10.1038/s41598-024-65221-y.

Regulation mechanism of EBV-encoded EBER1 and LMP2A on YAP1 and the impact of YAP1 on the EBV infection status in EBV-associated gastric carcinoma.

Sun Y, Shi D, Sun J, Zhang Y, Liu W, Luo B Virus Res. 2024; 343:199352.

PMID: 38462175 PMC: 10982081. DOI: 10.1016/j.virusres.2024.199352.

Exploring the Microbiome in Gastric Cancer: Assessing Potential Implications and Contextualizing Microorganisms beyond and Epstein-Barr Virus.

Shin W, Xie F, Chen B, Yu J, Lo K, Tse G Cancers (Basel). 2023; 15(20).

PMID: 37894360 PMC: 10605912. DOI: 10.3390/cancers15204993.

References

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F . Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014; 50(7):1330-44. DOI: 10.1016/j.ejca.2014.01.029. View

Colquhoun A, Arnold M, Ferlay J, Goodman K, Forman D, Soerjomataram I . Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015; 64(12):1881-8. DOI: 10.1136/gutjnl-2014-308915. View

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H . Gastric cancer. Lancet. 2016; 388(10060):2654-2664. DOI: 10.1016/S0140-6736(16)30354-3. View

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D . Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6):607-15. DOI: 10.1016/S1470-2045(12)70137-7. View

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S . Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4(9):e609-16. DOI: 10.1016/S2214-109X(16)30143-7. View

Blaser M . Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006; 7(10):956-60. PMC: 1618379. DOI: 10.1038/sj.embor.7400812. View

Perry S, Sanchez M, Yang S, Haggerty T, Hurst P, Perez-Perez G . Gastroenteritis and transmission of Helicobacter pylori infection in households. Emerg Infect Dis. 2007; 12(11):1701-8. PMC: 3372328. DOI: 10.3201/eid1211.060086. View

10.

Stoicov C, Saffari R, Cai X, Hasyagar C, Houghton J . Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene. 2004; 341:1-17. DOI: 10.1016/j.gene.2004.07.023. View

11.

Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001; 345(11):784-9. DOI: 10.1056/NEJMoa001999. View

12.

Wong B, Lam S, Wong W, Chen J, Zheng T, Feng R . Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291(2):187-94. DOI: 10.1001/jama.291.2.187. View

13.

Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, Shirota T . A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer. 2006; 119(1):196-201. DOI: 10.1002/ijc.21822. View

14.

Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M . Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. Am J Epidemiol. 2008; 168(12):1409-15. DOI: 10.1093/aje/kwn276. View

15.

Huang J, Zheng G, Sumanac K, Irvine E, Hunt R . Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2004; 125(6):1636-44. DOI: 10.1053/j.gastro.2003.08.033. View

16.

Rudi J, Kolb C, Maiwald M, Zuna I, von Herbay A, Galle P . Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Dig Dis Sci. 1997; 42(8):1652-9. DOI: 10.1023/a:1018849112533. View

17.

Yamaoka Y, Kodama T, Kashima K, Graham D . Antibody against Helicobacter pylori CagA and VacA and the risk for gastric cancer. J Clin Pathol. 1999; 52(3):215-8. PMC: 501082. DOI: 10.1136/jcp.52.3.215. View

18.

Parsonnet J, Friedman G, ORENTREICH N, Vogelman H . Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997; 40(3):297-301. PMC: 1027076. DOI: 10.1136/gut.40.3.297. View

19.

Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A . Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A. 2008; 105(3):1003-8. PMC: 2242726. DOI: 10.1073/pnas.0711183105. View

20.

Kwok T, Zabler D, Urman S, Rohde M, Hartig R, Wessler S . Helicobacter exploits integrin for type IV secretion and kinase activation. Nature. 2007; 449(7164):862-6. DOI: 10.1038/nature06187. View